C4 Therapeutics and Merck KGaA Partners for Oncogenic Proteins

C4 Therapeutics and Merck KGaA, Darmstadt, Germany, Team Up in Strategic Discovery Collaboration Against Critical Oncogenic Proteins

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) has announced a collaboration with Merck KGaA, Darmstadt, Germany, operating as EMD Serono in the U.S. and Canada, to develop two targeted protein degraders against oncogenic proteins within C4T's internal discovery pipeline.

Statement from CEO: C4 Therapeutics

Andrew Hirsch, President and CEO of C4 Therapeutics, expressed enthusiasm for the partnership, emphasizing its potential to transform cancer treatment. He highlighted the complementary strengths of both organizations and C4T's track record in developing innovative targeted protein degrader medicines.

Merck KGaA Leader on Collab

Paul Lyne, Head of Research Unit Oncology at Merck KGaA, Darmstadt, Germany, also emphasized the collaboration's importance in expanding Merck's portfolio in targeted protein degradation projects. Lyne mentioned the utilization of C4 Therapeutics' expertise to advance degrader candidates and improve patient outcomes.

Funding Post Collaboration

• According to the agreement, C4T will receive an upfront payment of $16 million and ongoing funding for research efforts. 
• The collaboration offers the potential for C4T to earn up to approximately $740 million in various milestone payments, along with royalties on future sales for each program.

Responsibilities Post Collab

C4T will utilize its TORPEDO® platform to discover degraders targeting oncogenic proteins, while Merck KGaA, Darmstadt, Germany, will handle clinical development and commercialization.

Futuristic Step

This collaboration marks a significant step in cancer therapy research, bringing together the strengths of C4 Therapeutics and Merck KGaA, Darmstadt, Germany, to address critical medical needs in oncology.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!